2023 annual financial data
Metagenomi Therapeutics 2023 Operating margin
Metagenomi Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was -175.38%.
Operating income was -78,492,000 USD and net income was -68,255,000 USD.
Operating cash flow was -91,409,000 USD.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 44,756,000 USD
- Operating income
- -78,492,000 USD
- Net income
- -68,255,000 USD
- Operating cash flow
- -91,409,000 USD